Vaccine Adjuvants Market Outlook:
Vaccine Adjuvants Market size was over USD 1.25 billion in 2025 and is anticipated to cross USD 2.14 billion by 2035, growing at more than 5.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of vaccine adjuvants is assessed at USD 1.31 billion.
The growth of the vaccine adjuvants market can be attributed to the growing prevalence of infectious and allergy diseases such as HIV/AIDS, tuberculosis (TB), malaria, and neglected infectious diseases along with increasing demand for advanced and improved vaccines. NTDs encompass a diverse group of infections caused by parasites, bacteria, fungi, viruses, and other non-communicable pathogens. In addition, there were 1.6 million deaths from TB in 2021 (including 187 000 HIV-positive individuals). According to the World Health Organization, TB is the 13th leading cause of death and the second leading infectious killer in the world after COVID-19. Vaccine adjuvants are substances that improve the effectiveness of vaccines. The growing prevalence of infectious diseases has caused an increase in demand for more effective vaccines, which has in turn contributed to greater research and development of new vaccine adjuvants.
In addition to these, factors that are believed to fuel the vaccine adjuvants market growth of vaccine adjuvants include an increase in financial support from governments and private organizations for the development of vaccines and the growing demand for safe and effective immunization are expected to have a positive impact on the growth of the global vaccine adjuvants market. In addition, funding for vaccine research and infectious disease research is expected to enhance the lucrative prospects for vaccine adjuvants. For instance, to prevent epidemics, detect disease threats, and respond rapidly and effectively to epidemics, the US government announced a funding of USD 122 million for Indian medical research institutes in June 2022.
